SCOPING REVIEW

OPEN ACCESS

Environmental and Economic Impacts of End-tidal Control of Volatile Anesthetics: A Scoping Review and Analysis

John W. Beard[1,*] iD, R. Ross Kennedy[2,3], James H. Philip[4], Mary Erslon[5], Weiqi Jiao[6], Hayden W. Hyatt[6] and Halit O. Yapici[6]

[1]Patient Care Solutions, GE HealthCare, Chicago, Illinois, USA

[2]Department of Anaesthesia, University of Otago- Christchurch, Christchurch, Aotearoa, Newzealand

[3]Christchurch Hospital, Te Whatu Ora, Waitaha | Canterbury, Aotearoa, Newzealand

[4]Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Mass General Brigham Healthcare, Harvard Medical School, Boston, MA, USA

[5]Pre operative medicine, Mary Erslon, Limited Liability Corporation, St. Louis, MO, USA

[6]Department of Health Economics and Outcomes Research, Boston Strategic Partners Incorporated, Boston, MA, USA

Abstract:

Objective: This review aimed to assess the environmental and economic impacts of End-tidal Control (ET control) compared to manual clinician administration of inhaled anesthetics.

Methods: A scoping literature review was conducted to evaluate the consumption of anesthetic agents when using the Et Control software medical device compared to standard care (manual clinician adjustments) and the associated environmental/economic outcomes. Data were pooled across studies, and standardized mean difference, non-standardized weighted mean difference, and relative reduction in anesthetic agent usage between Et Control and manual adjustments were calculated. Annual reductions in hospital costs and greenhouse gas emissions for a representative 592-bed academic medical center were calculated.

Results: Eight out of the ten identified studies demonstrated that Et Control reduced anesthetic agent usage rates compared to manual administration. Based on the compiled evidence, Et Control results in a mean decrease of anesthetic agent usage by 32.2% for desflurane, 30.1% for isoflurane, and 4.1% for sevoflurane. The annual cost-savings and environmental impact for a large academic medical center using Et Control instead of manual administration is conservatively estimated to be $95,536 ($16,136 per 100 beds), with greenhouse gas emissions reduced by 434,345 kg (73,360 per 100 beds) in CO_2 equivalencies (~100 motor vehicle emissions annually).

Conclusion: Our focused review and analysis indicate that Et Control reduces greenhouse gas emissions of anesthesia practice while also conferring cost-savings. The ability of semi-closed loop anesthesia systems to facilitate low-flow anesthesia warrants the need for future research to understand the full scope of environmental and economic impacts.

Keywords: End-tidal control, Inhaled anesthetic, Automated anesthesia, Semi-closed loop anesthesia, General anesthesia, Cost-savings, Greenhouse gas emissions, Environment.

1. INTRODUCTION

Inhalational anesthetics are traditionally delivered by clinicians with frequent manual adjustments to anesthetic concentrations and fresh gas flows. Recent advancements in anesthesia system technologies allow for semi-closed loop adjustments in anesthetic and oxygen gas composition and flow rates to meet clinical targets set by the provider [1-4]. Various anesthesia systems are available worldwide, while only End-tidal Control (Et Control, GE HealthCare, Chicago, IL) is currently approved for use in the United States with the Aisys™ CS^2 anesthesia delivery system (GE HealthCare, Chicago, IL).

Semi-closed loop anesthesia delivery systems have been shown to successfully achieve the desired anesthesia end-tidal targets and significantly decrease the incidence of undershooting or overshooting anesthetic or oxygen levels [5]. These systems have also been shown to significantly reduce the number of adjustments to gas flows and anesthetics required during patient care and facilitate the delivery of low-flow inhaled anesthesia [2-4]. By facilitating low-flow anesthesia, semi-closed loop systems reduce anesthetic gas consumption during surgical procedures, which has important environmental and economic advantages [1-4].

As indicated by the most recent report by the United Nations' Intergovernmental Panel on climate change, reduced environmental emissions across all economical sectors and industries, including healthcare, are needed to avoid irreversible change to the world's climate [6]. Greenhouse gas emissions are the largest contributor to the rise in global temperatures [7]. In the United States, the need to accelerate reductions in healthcare-associated greenhouse gas emissions, which make up ~8.5% of U.S. greenhouse gas emissions, has recently been addressed by both the Center for Medicare and Medicaid Services and the Department of Health and Human Services [8-10].

The fluorinated anesthetic agents sevoflurane, isoflurane, and desflurane are widely used in anesthesiology due to their stability, favorable toxicity profiles, and efficacy [11]. Unfortunately, these agents undergo little metabolism in the body and are most commonly released into the atmosphere through the Waste Anesthetic Gas Disposal System (WAGS) utilized in the operating room [12]. In reference to the 100-year Global Warming Potential (GWP$_{100}$), a metric used to quantify the radiative and atmospheric properties of a particular gas relative to CO_2, sevoflurane, isoflurane, and desflurane has a respective GWP$_{100}$/kg of 127, 565, and 2720 [13, 14]. In other words, these gases are ~120-2700x more potent in their warming effects in the atmosphere than CO_2. These potent anesthetic agents contribute up to 5% of hospital's total greenhouse gas emissions and have become a focus of strategies to develop more environmentally sustainable practices in anesthesia [15]. The potential to reduce anesthetic gas usage through semi-closed loop anesthesia delivery systems presents an important opportunity to contribute to climate goals.

Et Control was introduced into clinical practice outside the United States in 2010 and is used in over 100 countries [1-4, 16]. In March 2022, the FDA approved Et Control as a Class III software medical device, and the first semi-closed loop inhaled anesthesia delivery technology for use in the United States [17, 18]. We are conducting this analysis as a thorough review of the clinical experience with Et Control to inform the clinical community who are not familiar with semi-closed loop delivery of oxygen and inhaled anesthetics. We have focused this analysis on Et Control to provide evidence that coincides with the U.S. market's introduction of new clinical users. This scoping review provides a thorough examination of the environmental (as assessed by greenhouse gas emissions) and economic impacts (as assessed by recurrent cost-savings) of Et Control through reductions in anesthetic consumption when compared to manual anesthetic delivery.

2. METHODS

2.1. Study Design and Literature Review

A focused, scoping literature review was conducted to assess the environmental (*i.e.*, greenhouse gas emissions) and economic outcomes (*i.e.*, recurrent cost-savings) of Et Control when compared to standard care (manual clinician adjustments of gas flows and anesthetic agents). Outcome measures of interest included anesthetic agent utilization rates, assessment of greenhouse gas emissions, and economic evaluations by studies comparing Et Control and standard care. As the present study extracted data from previously published sources, no primary data collection involving human participants was undertaken. Therefore, ethical approval for this study was not required. The analyses conducted in this paper strictly adhere to the ethical guidelines and regulations established by the original data sources that provided anesthetic agent utilization rates [1-4, 19-24].

An electronic database search was conducted for studies performed in adult populations that were published between January 1, 2013, and February 28, 2023. Databases that were searched include PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar. The search strategy applied to Pubmed and Embase included the terms "end-tidal, end-tidal control, anesthesia, automatic control, manual control, semi-closed loop, automated gas control, closed loop, and conventional." Studies were also manually searched by retrieving studies cited by publications identified in the electronic database search, review papers, and communications with relevant experts/principal investigators. No geographic restrictions were applied; however, only studies with the full text written in English were eligible for inclusion. For anesthetic agent utilization rates, studies were included if they reported usage rates for isoflurane, desflurane, and sevoflurane; these anesthetic agents were selected due to their predominant use during inhalation anesthesia and relevance to the clinical community [11]. Studies were excluded from the analysis if the mean or Standard

Deviation (SD) could not be derived based on the provided data. A full-text review of the identified studies was conducted by two separate reviewers to assess the robustness of sample size, use of Et Control, and the relevance of reported findings (*e.g.*, gas utilization rates). If further clarification on study methodology or findings were required, correspondence was solicited from the respective authors or journal editors in accordance with Cochrane policy [25].

2.2. Data Extraction, Preparation, and Analysis

2.2.1. Anesthetic Agent Utilization Rates

Based on the evidence compiled from the literature review, we extracted data from relevant studies on flow rate, anesthetic agent utilization rates, and the number of cases of anesthesia delivered by Et Control or manual clinician adjustments. Data for anesthetic agent utilization rates were extracted as the mean volume (mL) per hour usage of the anesthetic agent; in cases where this value was not provided, mL/hour usage rates were calculated based on the absolute volume used normalized to the longest reported timepoint of anesthesia for the respective volume [3, 4, 20, 21].

Data across studies were pooled per each respective anesthetic agent, and the Standardized Mean Difference (SMD) and non-standardized weighted mean difference were calculated using the published mean and SD for anesthetic agent usage rates. For studies that only reported mean and 95% CI or *p*-values, the SD was derived according to the Cochrane Handbook of Systematic Reviews [26]. The mean and SD were derived according to Wan *et al.* for studies that only provided the median and the 25th and 75th percentiles [27]. For articles that provided the median and IQR (75th-25th percentile), the mean was assumed to be the median, and the SD was derived according to Wan *et al.* [27]. Between-study heterogeneity of the analysis was quantified using the I^2 statistic [28].

We quantified the average proportional reduction in each anesthetic across studies. To derive the relative reduction in anesthetic agent usage with Et Control or manual adjustments, we first calculated the percent difference in means (*i.e.*, (Et Control – Manual)/Manual *100). For each gas, the relevant study's percent difference was weighted by the corresponding total sample size (*i.e.*, the sum of the sample size of the Et Control and Manual arms) to derive a weighted mean relative change and its 95% confidence interval. These analyses were performed using Stata/MP 17.0 for Windows (StataCorp, LLC College Station, TX), and all *p*-values < 0.05 were considered statistically significant.

2.2.2. Annual Anesthetic Agent Usage

Annual volatile anesthetic agent consumption quantities were modeled based on a 592-bed "large academic medical center" from Zuegge *et al.*, which included 31,779 anesthetics delivered in 43 operating rooms plus Non-Operating Room Anesthetizing (NORA) locations [29]. Annual anesthetic consumption is represented as bottles of desflurane (1,354), sevoflurane (3,663), and isoflurane (407) [29]. Values from Zuegge *et al.* were used to model anesthetic agent consumption representative of a large academic medical center that treats diverse patient cases and medical conditions, where such comprehensive data on hospital-wide anesthetic agent usage is limited [29].

2.2.3. Economic Impact of Et Control

The potential for economic benefits was assessed by applying the relative proportional reduction in anesthetic agent utilization to the consumption quantities of a representative large academic medical center. The annual savings were calculated using the reduction in the use of anesthetic agents and the cost per bottle of a respective anesthetic agent obtained from Zuegge *et al.* and inflated to 2023 USD using the U.S. consumer price index [29, 30].

2.2.4. Environmental Impact of Et Control

To assess the potential environmental impacts of Et Control, we estimated the reductions in CO_2 Equivalency (CDE) that may occur due to decreased anesthetic agent usage with Et Control compared to manual clinician adjustments for a large academic medical center [29]. Using the estimated reductions in CDE, the GWP_{100} for each respective anesthetic agent was calculated, accounting for the hepatic metabolism of sevoflurane as 3%, isoflurane 0.2%, and desflurane 0.02% [1, 13, 14]. Reduction in annual CDE was estimated based on the calculated relative reduction in anesthetic agent usage between Et Control and manual adjustments. CDE of a particular gas was obtained by multiplying the mass emitted in kilograms/hour and the known GWP_{100} of the agent, such that (mL agent) × (agent density, in g/mL) × (1 kg/1000 g) × (GWP agent) = CDE of the agent [29].

3. RESULTS

3.1. Review of Anesthetic Agent Utilization Rates

Ten studies were identified that evaluated anesthetic agent utilization rates, assessed environmental impacts, and assessed economic outcomes when comparing Et Control and manual clinician adjustment for anesthesia delivery (Fig. **1**). Study characteristics are summarized in Table **1**. Of the identified studies, eight assessed outcomes for sevoflurane, five for desflurane, and two for isoflurane. Eight out of the ten studies indicated that anesthetic agent usage rates were decreased when Et Control was used for anesthetic delivery compared to manual adjustments [1-3, 19-22, 24], while two studies found a higher usage rate of sevoflurane with Et Control compared to manual adjustments when using equivalent fresh gas flow rates [4, 23].

Fig. (1). PRISMA flow diagram.
Note: Record counts identified from databases and expert recommendations were not mutually exclusive.

Table 1. Characteristics of the included studies after full-text review.

Study/Refs.	Geography	Study Design	Study Population	No. of Patients	The Flow Rate of Anesthesia Machine	Measured Anesthetic Agent	Measure Timeframe
Arora *et al*, 2020 [3]	India	RCT	Patients undergoing surgery requiring general anesthesia	EtC = 42 MC = 42	EtC = 1 L/min MC = 1 L/min	Desflurane	2 hours after induction
Kandeel *et al*, 2017 [19]	Egypt	RCT	Patients undergoing living donor right hepatectomy	EtC = 20 MC = 20	EtC = 2 L/min MC = 2 L/min	Sevoflurane	Mean anesthesia duration: MC = 390 minutes EtC = 399 minutes
Lucangelo *et al*, 2013 [20]	Italy	Prospective observational	Patients undergoing elective abdominal surgery	EtC = 40 MC = 40	EtC = 1 L/min MC = 1 L/min	Sevoflurane	Surgeries >1 hour in duration
MASTER trial [24]	United States	RCT	Patients scheduled for non-emergent surgery	EtC = 100 MC = 108	EtC = NS MC = 0.5 L/min	Desflurane, Sevoflurane, Isoflurane	From induction to disconnect
Mostad *et al*, 2021 [21]	Norway	RCT	Patients undergoing robot-assisted laparoscopic surgery	EtC = 37 MC = 34	EtC = NS MC = 1 L/min	Desflurane	60 minutes after initiation of desflurane

(Table 3) contd.....

Study/Refs.	Geography	Study Design	Study Population	No. of Patients	The Flow Rate of Anesthesia Machine	Measured Anesthetic Agent	Measure Timeframe
Potdar *et al*, 2014 [22]	India	RCT	Patients undergoing laparoscopic abdominal or pelvic surgeries	EtC = 100 MC = 100	EtC = 1.5 L/min MC = 1.5 L/min	Sevoflurane	Surgeries 30 minutes - 4 hours in duration
Singaravelu *et al*, 2013 [2]	United Kingdom	Prospective, service evaluation and clinical audit	Patients undergoing gynaecological procedures	EtC = 117 MC = 20	EtC = NS MC = NS	Sevoflurane, Desflurane	Surgeries >60 minutes in duration
Skalec *et al*, 2017 [4]	Poland	Prospective, observational	Patients undergoing abdominal and thyroid surgeries	EtC = 35 MC = 39	EtC = 1 L/min MC = 1 L/min	Sevoflurane	Median duration of anesthesia: MC = 125 minutes EtC = 105 minutes
Tay *et al*, 2013 [1]	Australia	Prospective observational	Patients undergoing elective and emergency surgery	EtC = 1,810 MC = 1,865	EtC = 0.5 L/min MC = 0.5 L/min (Desflurane, Isoflurane) MC = 2 L/min (Sevoflurane)	Desflurane, Sevoflurane, Isoflurane	Mean duration of anesthesia: MC = 69 minutes EtC = 64 minutes
Wetz *et al*, 2017 [23]	Germany	CCT	Patients undergoing elected surgeries	EtC = 30 MC = 34	EtC = 0.5 L/min MC = 0.5 L/min	Sevoflurane	1 hour from connection

Abbreviations: EtC, Et Control; MC, Manual control; NS, Not specified; RCT, Randomized controlled trial; CCT, Controlled clinical trial.

Table 2. Anesthetics usage data input for analysis, with original study results standardized in the format of mean value with standard deviations.

Anesthetic Agent	Et Control		Manual Control		Study/Refs.
	No. of patients	Agent usage (Mean ± SD, mL/hr)	No. of patients	Agent usage (Mean ± SD, mL/hr)	
Desflurane					
	42	14.36 ± 2.86[a]	42	16.49 ± 2.86[a]	Arora *et al.*, 2020 [3]
	27	3.61 ± 1.44	19	4.89 ± 2.59	MASTER Trial [24]
	37	15.20 ± 1.80	34	25.80 ± 1.10	Mostad *et al.*, 2021 [21]
	74	17.00 ± 6.47[a]	4	33.00 ± 6.28[a]	Singaravelu *et al.*, 2013 [2]
Sevoflurane					
	20	12.60 ± 2.60	20	15.00 ± 2.90	Kandeel *et al.*, 2017 [19]
	40	7.00 ± 1.80[b]	40	7.40 ± 1.35[b]	Lucangelo *et al.*, 2013 [20]
	56	7.17 ± 2.12	82	7.54 ± 2.10	MASTER Trial [24]
	100	10.20 ± 3.14[a]	100	12.00 ± 3.14[a]	Potdar *et al.*, 2014 [22]
	43	9.00 ± 1.63[a]	16	14.00 ± 4.69[a]	Singaravelu *et al.*, 2013 [2]
	35	7.03 ± 2.24[c]	39	4.94 ± 1.36[c]	Skalec *et al.*, 2017 [4]
	30	7.13 ± 0.83[b]	34	6.10 ± 0.97	Wetz *et al.*, 2017 [23]
Isoflurane					
	17	5.57 ± 2.16	15	7.97 ± 2.08	MASTER Trial [24]

Abbreviations: SD, Standard deviation.

[a]For studies that reported mean and 95% CI values, or mean and p-values, SD was derived using published methodology from Higgins *et al*. [26].

[b]For studies that reported median values and the 25th and 75th percentiles, the mean value and SD were derived using published methodology from Wan *et al*. [27].

[c]For studies that reported median values and interquartile ranges, the mean value was assumed to be equivalent to the reported median value, and SD was derived using published methodology from Wan *et al*. [27].

Nine studies were included for further analysis of the economic and environmental benefits due to Et Control-associated reductions in anesthetic agent utilization rates. The mean values and SD for anesthetic agent usage rates utilized for our analysis are provided in Table **2**. Tay *et al*. was excluded from further analysis because the data reported was not sufficient to derive a reliable mean/SD value for anesthetic agent usage [1].

To measure an overall/average impact on anesthetic agent utilization when utilizing Et Control compared to manual clinician adjustments across studies, the SMD and non-standardized weighted mean difference were calculated for each respective gas. Significant differences were detected for the SMD of desflurane (SMD, -1.3; 95% CI, -1.62 to -0.97; *p*<0.001), sevoflurane (SMD, -0.19; 95% CI, -0.35 to -0.03; *p*=0.019), and isoflurane (SMD, -1.13; 95% CI, -1.88 to -0.38; *p*=0.003); desflurane and isoflurane had large effect sizes (absolute SMD value

>0.8) (Table **3**). In terms of relative reductions, Et Control resulted in significant decreases in usage rates of desflurane and sevoflurane that resulted in a 32.2% (95%CI, -33.9% to -30.5%; *p*<0.001) and 4.1% (95%CI, -5.6% to -2.5%; *p*<0.001) lower relative anesthetic agent utilization rate compared to manual clinician adjustments (Table **3**). Et Control resulted in significant decreases in anesthetic agent utilization rates for desflurane and isoflurane with a non-standardized weighted mean difference of -7.32 mL/hour (95% CI, -7.86 to -6.78; *p*<0.001) and -2.4 mL/hour (95% CI, -2.87 to -0.93; *p*=0.001), respectively, compared to manual adjustments.

Since there were relatively few studies that met the inclusion criteria for this review, heterogeneity in the study protocols and patient populations was tested across studies. The I^2 statistic was significant (*p*<0.001) for pooled studies assessing desflurane (I^2=96.8%), sevoflurane (I^2=93%), and isoflurane (I^2=100%).

3.2. Economic Evaluation and Greenhouse Gas Emission Assessment

The economic evaluation and greenhouse gas emission assessment of decreased anesthetic agent usage with Et Control compared to manual adjustments are displayed in Tables **4** and **5**. Based on the mean relative reduction of anesthetic agent usage across all studies identified by the scoping literature review, our findings reveal that cost reductions occurred on a yearly basis with the use of Et Control compared to manual adjustments (Table **4**). The annual cost-savings for a large academic medical center using Et Control instead of manual adjustments was estimated to be $95,536 ($16,136 per 100 beds), with decreased usage of desflurane accounting for the largest portion of cost-savings ($80,249 for the center; $13,554 per 100 beds) followed by a reduction in costs for sevoflurane ($14,154 for the center; $2,390 per 100 beds). The reduced usage of anesthetic agents with Et Control compared to manual adjustments also resulted in a substantial decrease in greenhouse gas emissions. Et Control decreased the greenhouse gasses emitted by anesthetic agents equivalent to a reduction of 434,345 CDE (73,360 per 100 beds) annually per hospital, with decreased usage of desflurane being the largest contributor with an annual reduction of 417,004 CDE (70,431 per 100 beds) followed by a decrease of 10,379 CDE (1,753 per 100 beds) for isoflurane (Table **5**).

4. DISCUSSION

The findings from our review and analysis reveal that Et Control is associated with economic and environmental benefits compared to manual clinician administration of inhaled anesthesia. These findings come from studies conducted in multiple countries where Et Control has been successfully implemented, and this is the first comprehensive review to assess the impact of Et Control as a pooled analysis of published results. The benefits of Et Control are derived from the ability of Et Control to reduce the consumption of volatile anesthetic agents

Table 3. Standardized mean differences, weighted mean differences, and relative proportional reduction in Anesthetic agent usage between the Et Control delivery system and manual control.

Anesthetic Agent	No. of Patients	Agent Usage (SMD, 95% CI)	*p* value	Agent usage (WMD, 95% CI, mL/hr)	*p* value	Agent Usage (RPR, 95% CI)	*p* value
Desflurane	EtC = 180 MC = 90	-1.30 (-1.62, -0.97)	<0.001	-7.32 (-7.86, -6.78)	<0.001	-32.2% (-33.9% to -30.5%)	<0.001
Sevoflurane	EtC = 324 MC = 331	-0.19 (-0.35, -0.03)	0.019	0.20 (-0.08, 0.49)	0.164	-4.1% (-5.6% to -2.5%)	<0.001
Isoflurane	EtC = 17 MC = 15	-1.13 (-1.88, -0.38)	0.003	-2.40 (-2.87, -0.93)	0.001	-30.1%	NA

Abbreviations: EtC, Et Control; MC, Manual control; No., number; SMD, Standardized mean difference; WMD, Weighted mean difference; RPR, Relative proportional reduction.

Table 4. Economic impact of using ET control *vs.* manual control to deliver volatile anesthetic agents for a U.S. hospital.

Anesthetic Agent	Annual Consumption[a]: MC (bottle)	Annual Consumption[b]: EtC (bottle)	Average Purchasing Price per Bottle[a] (USD)	Annual Cost Savings (USD)
Desflurane	1,354	918	$184	$80,248.89
Sevoflurane	3,663	3,514	$95	$14,154.22
Isoflurane	407	284	$8	$933.08
Total	**5,424**	**4,717**		**$95,336.18**

Abbreviations: MC, Manual control; EtC, Et Control;

[a]Annual volatile anesthetic agent consumption quantities and average purchasing prices were obtained from a 592-bed academic medical center as part of the University of Wisconsin Health in 2015, published in Zuegge *et al*. [29]. All cost values were inflated to 2023 USD using the US consumer price index, calculated by the US Inflation Calculator [30].

[b]Annual volatile anesthetic agent consumption quantities in the EtC group were estimated based on the relative usage reduction rates reported in Table **3**.

Table 5. Impact on greenhouse gas emissions using ET Control *vs.* manual control to deliver volatile anesthetic agents for a U.S. hospital.

Anesthetic Agent	Annual Consumption[a]: MC (mL)	Annual Consumption[b]: EtC (mL)	Gas Density, g/ml	GWP$_{100}$ per kg [13, 14] GWP$_{100}$	Annual CDE reduction[c], kg
Desflurane	324,960	220,290	1.465	2720	417,004.07
Sevoflurane	915,750	878,571	1.52	127	6,961.81
Isoflurane	40,700	28,445	1.502	565	10,378.97
Total	**1,281,410**	**1,127,306**			**434,344.84**

Abbreviations: MC, Manual control; EtC, Et Control; GWP$_{100}$, 100-year Global warming potential; CDE, Carbon dioxide equivalency.

[a]Annual volatile anesthetic agent consumption quantities were calculated based on the number of bottles purchased per year and the volume (mL) per bottle for each volatile agent, obtained from a 592-bed academic medical center as part of the University of Wisconsin Health in 2015, published in Zuegge *et al.* [29].

[b]Annual volatile anesthetic agent consumption quantities in the EtC group were estimated based on the relative usage reduction rates reported in Table **3**.

[c]Carbon dioxide equivalency (CO$_2$ equivalency [CDE]) of a particular gas was obtained by multiplying the mass emitted in kilograms and the known GWP$_{100}$ of the agent factoring in the hepatic metabolism sevoflurane as 3%, isoflurane 0.2% and desflurane 0.02% [1]. Specifically, CDE of the agent = (ml/hr agent) × (agent density, in g/mL) × (1 kg/1000 g) × (GWP$_{100}$ agent) × (1 - % hepatic metabolism).

through breath-by-breath monitoring of end-tidal gases and fresh gas flow and vaporizer adjustments. These frequent adjustments reduce manual, repetitive tasks required of the provider, and, on average, the clinician plus Et Control delivers a more stable, accurate, and precise anesthetic at lower flows than the clinician alone. Our analysis of the published literature indicated that Et Control may reduce anesthetic agent usage by up to ~32% (*e.g.*, desflurane) compared to manual administration, resulting in cost-savings for anesthetic agents and a reduction in greenhouse gas emissions. Our findings provide a comprehensive review of the Et Control literature to inform decision-makers in the assessment of potential environmental and economic benefits conferred by Et Control for their facility or system.

Previous studies have independently estimated the economic benefits of Et Control when compared to manual clinician adjustments. Singaravelu *et al.* reported a reduction in the consumption of sevoflurane and desflurane when using Et Control, which yielded a 40-55% decrease in anesthetic agent costs [2]. Although excluded from our analysis, Tay *et al.* found that the use of Et Control reduced anesthetic agent usage, resulting in a 27% decrease in anesthetic agent costs for a hospital with ~7,500 general anesthesia procedures per year [1]. Potdar *et al.* and Arora *et al.* also reported decreased anesthetic agent usage, which resulted in decreased costs of 15% and 14%, respectively [3, 22]. These estimates of cost-savings are consistent with the pooled findings in this study and demonstrate that although underlying study methodologies may vary, a consistent trend exists for the reduction in anesthetic agent usage when Et Control is used in place of manual administration.

Since the majority of studies included in our analysis utilized equivalent fresh gas flow rates between Et Control and manual administration (*e.g.*, 1.5L/min *vs.* 1.5L/min), it is possible that greater waste reduction and cost-savings could be realized if Et Control is used to deliver anesthesia at flow rates lower than what is commonly used in clinical practice. In fact, the evidence from Singaravelu *et al.* indicates that the use of Et Control can result in a mean

decrease of fresh gas flow rates by over 50% compared to flow rates used during manual clinician administration [2]. This observation is supported by findings from Kandeel *et al.*, which report a 72% reduction in sevoflurane consumption when using a fresh gas flow rate of 0.5L/min with Et Control compared to a flow rate of 2L/min with manual adjustments [19]. Lower fresh gas flow rates are essential for economic and environmental (*i.e.*, greenhouse gas emissions) benefits to be realized, as fresh gas flow rates are tied directly to the consumption of anesthetic agents [31].

Our findings revealed that utilization of Et Control could result in an estimated cost savings of $95,536 ($16,136 per 100 beds) for a large academic medical center through reductions in anesthetic agent consumption. Edmonds *et al.* have previously estimated cost-savings for implementing lower flow rates across a tertiary medical center in the United States [31]. They estimated that a flow rate of 0.5L/min could result in over $91,000 higher cost-savings (in 2023 USD) compared to a flow rate of 2.5L/min. Applying the relative reduction rates in anesthetic agent consumption when anesthesia is delivered with lower fresh gas flow rates according to Edmonds *et al.* [31], utilizing Et Control to decrease the mean fresh gas flow rate from 2.0L/min to 1.0L/min or 0.5L/min in the current findings would result in an estimated cost-savings of $181,587 ($30,670 per 100 beds) and $264,932 ($44,747 per 100 beds) for sevoflurane usage, respectively. Collectively, these values exemplify the potential of Et Control to confer greater cost-savings when used to deliver anesthesia at fresh gas flow rates lower than what is commonly used during manual clinician adjustments. The anesthetic usage proportions and fresh gas flow rates of clinical practices may vary significantly, thus requiring individualized analysis to determine the potential impact of Et Control.

This analysis estimated that the average decrease in anesthetic agent usage results in a reduction of yearly greenhouse gas emissions by over 430,000 CDE (~73,000 per 100 beds) [32]. This represents a ~29% decrease in greenhouse gas emissions from anesthetic agents and is

equivalent to removing the emissions of ~100 U.S. motor vehicles annually (48,874 gallons or 185,008 liters of gasoline consumed) according to the average vehicle emission values provided by the United States Environmental Protection Agency (EPA) [32]. Although most studies identified by our scoping literature review alluded to the potential for environmental benefits [3, 21-23], only one study assessed the environmental impact of Et Control [1]. Tay *et al*. found that the use of Et Control resulted in a 44% decrease in greenhouse gas emissions compared to manual adjustments [1]. Notably, the reductions in greenhouse gas emissions reported by Tay *et al* [1]. are higher than the estimates provided by our current analysis. In this regard, it is plausible that even greater decreases in emissions would be observed if Et Control is used to decrease fresh gas flow rates lower than what is currently used in clinical practice [2, 31]. The choice of fresh gas flows for a practice or an individual may be due to several reasons, including concerns about safety at low gas flows and the possibility of inadequate anesthesia and hypoxemia. Et Control has been demonstrated to reliably achieve both end-tidal anesthetic and oxygen targets, thus potentially offsetting safety concerns with low flows and providing the confidence to practice low-flow anesthesia and further reduce greenhouse gas emissions. Worth noting, the use of fresh gas flow rates less than 1L/min with sevoflurane has been avoided by some clinicians due to concern of nephrotoxicity in rodents hypothesized as a result of compound A production [33]. However, the evidence supporting compound A production during low-flow anesthesia in humans has been disputed, and robust evidence indicates that sevoflurane can be safely used during low-flow anesthesia [34, 35].

Overall, our assessment of the literature revealed a limited number of relevant studies. The studies included in our analysis employed heterogeneous methodologies (*e.g.*, patient populations and target fresh gas flow rates), which was supported by a significant I^2 statistic. To account for this, our approach utilized the relative proportional reduction rate for estimations of economic and environmental impacts in order to provide additional internal control for comparing findings across studies. Nonetheless, caution may be warranted for interpreting the findings given the heterogeneous protocols utilized, which may result in over or underestimation of the underlying findings. For instance, our findings revealed modest reductions in sevoflurane usage with Et Control. The majority of studies found a decrease in sevoflurane consumption while using Et Control compared to manual adjustments [2, 19, 20, 22, 24]. Among these, Kandeel *et al*. had prior published comments addressing potential data concerns and considerations, such as the primary driver for differences between delivery methods being the ability of Et Control to maintain fresh gas flow rates lower than manual control when used at flow rates of 0.5L/min [19, 36, 37]. Following the solicitation of responses from the authors and the journal editor, the authors were not able to gain additional clarifications on these points. Of note, this study accounted for only ~6% of the total patients in the current analysis who were administered sevoflurane between ET Control and manual control. The exclusion of Kandeel *et al*. would not impact the directionality of our findings and would decrease the estimated relative proportional reduction of sevoflurane usage with Et Control by 0.78% [19].

Two separate studies also observed an increase in sevoflurane usage [4, 23]. While it is difficult to fully understand the rationale for increased sevoflurane usage in these studies, given the provided study methods, is it plausible that marginally higher flow rates with Et Control may have contributed to these discrepancies. For example, the study by Wetz *et al*. required clinician researchers to not alter fresh gas flow rates from a 0.5L/min target and for clinicians to only make adjustments to gas composition; although Et Control was also utilized at a fresh gas flow rate of 0.5L/min, Et Control can adjust flow rates as needed to achieve target end-tidal gas concentrations. In this manner, it is plausible that these deviations may have resulted in an increased sevoflurane usage compared to clinicians who were required to be hyper-vigilant of maintaining targets using only alterations in gas composition. It is also possible that higher fresh gas flow rates during induction of anesthesia with Et Control were present based on factory defaults, whereas the manual group selected lower rates. Additional studies using real-world evidence collected in the United States will add to the clinical knowledge base on Et Control and contribute to ongoing clinical applications.

4.1. Limitations

Our analysis has several limitations. First, while the anesthesia machines used were all Aisys CS^2 Anesthesia Systems (GE Healthcare) with Et Control, protocol heterogeneity may have contributed to variable anesthetic agent usage. Second, desflurane represented a large portion of our modeled hospital-wide anesthetic agent usage, which may have led to an overestimation of the impact of greenhouse gas emissions. Sevoflurane is increasingly becoming the preferred anesthetic agent used by anesthesia professionals, especially given the large greenhouse gas effect of desflurane [35]. Hence, our overall estimations of greenhouse gas emissions may be overestimated for hospital systems utilizing a larger proportion of sevoflurane; in this case, the relative reduction values per respective anesthetic agent can be utilized to appropriately estimate the environmental benefits for a given hospital system. Importantly, our findings of significantly lower sevoflurane usage with Et Control indicate the potential for environmental benefits to occur when compared to manual adjustments. Third, the inclusion of studies that utilized equivalent fresh gas flow rates between Et Control and manual administration may diminish the benefits of Et Control by not fully utilizing the low-flow capabilities of the system. Fourth, the diversity of countries where studies were conducted limits the opportunity to pool data from a specific geography. However, the diversity of sites may also suggest broad generalizability of this study's findings, including in the United States, where Et Control has only recently received FDA approval. Lastly, for those interested in a comprehensive return-on-investment analysis, this study does not include costs associated with

acquiring Et Control. The costs of implementing Et Control were not assessed due to variations in the pricing models for such technologies that occur across different regions, institutions, and timeframes. Further, the costs associated with these systems may benefit from economies of scale, especially in larger healthcare facilities with multiple operating theatres. The costs associated with implementing automated anesthesia systems can also evolve over time, potentially making specific cost figures less relevant or subject to frequent change. Accounting for these factors exceeded the scope of this review and prohibited an in-depth cost analysis.

CONCLUSION

Our findings demonstrate that Et Control can confer recurrent cost-savings and reductions in greenhouse gas emissions by significantly reducing the use of volatile anesthetic agents during inhaled anesthetic administration when compared to the manual process. Our analysis of the included studies indicates that the reduced anesthetic agent usage may conservatively result in the potential for cost-savings of over $95,000 (2023 USD) for a large academic medical center (when using similar proportions of anesthetic agents as the modeled center) while providing environmental benefits that are equivalent to eliminating the annual emissions of ~100 U.S. motor vehicles. Additional reductions in costs and greenhouse gas emissions are expected when the low-flow capabilities of Et Control are maximally utilized to reduce fresh gas flows.

AUTHORS' CONTRIBUTIONS

J.B., W.J., H.H., and H.Y.: Participated in the design of this study; J.B. and W.J.: Screened titles and abstracts from the database search; H.Y. and H.H.: Independent evaluation of identified studies for their eligibility; J.B., R.K., J.P., M.E., W.J., H.H., and H.Y.: Performed the analysis. All authors reviewed and edited the writing for this manuscript. All authors approved of the final version of this manuscript.

LIST OF ABBREVIATIONS

Et Control	=	End-tidal Control
WAGS	=	Waste anesthetic gas disposal system
GWP100	=	100-year global warming potential
SMD	=	Standardized mean difference
SD	=	Standard deviation
IQR	=	Interquartile range
CDE	=	CO_2 equivalency
SD	=	Standard Deviation
SMD	=	Standardized Mean Difference
NORA	=	Non-Operating Room Anesthetizing
CDE	=	CO_2 Equivalency

CONSENT FOR PUBLICATION

Not applicable.

STANDARDS OF REPORTING

PRISMA guidelines and methodology were followed.

AVAILABILITY OF DATA AND MATERIALS

The data and supportive information are available within the article.

SUPPLEMENTARY MATERIAL

PRISMA checklist is available as supplementary material on the publisher's website along with the published article.

REFERENCES

[1] Tay S, Weinberg L, Peyton P, Story D, Briedis J. Financial and environmental costs of manual *versus* automated control of end-tidal gas concentrations. Anaesth Intensive Care 2013; 41(1): 95-101.
http://dx.doi.org/10.1177/0310057X1304100116 PMID: 23362897

[2] Singaravelu S, Barclay P. Automated control of end-tidal inhalation anaesthetic concentration using the GE Aisys Carestation™. Br J Anaesth 2013; 110(4): 561-6.
http://dx.doi.org/10.1093/bja/aes464 PMID: 23293274

[3] Arora K, Swami A, Puppala P, Rai A. Comparative study of automated end tidal control *versus* manual fresh gas flow adjustment with respect to gas usage and delivery during low flow anesthesia. Anesthesia and Critical Care 2020; 2(2): 39-51.

[4] Skalec T, Górecka-Dolny A, Zieliński S, Gibek M, Stróżecki Ł, Kübler A. Comparison of anaesthetic gas consumption and stability of anaesthesia using automatic and manual control over the course of anaesthesia. Anaesthesiol Intensive Ther 2017; 49(1): 34-9.
http://dx.doi.org/10.5603/AIT.2017.0008 PMID: 28362031

[5] Brogi E, Cyr S, Kazan R, Giunta F, Hemmerling TM. Clinical performance and safety of closed-loop systems: a systematic review and meta-analysis of randomized controlled trials. Anesth Analg 2017; 124(2): 446-55.
http://dx.doi.org/10.1213/ANE.0000000000001372 PMID: 27482773

[6] Hoesung Lee KC, Dasgupta D, Gerhard, Krinner AM, *et al.* Synthesis report of the IPCC Sixth Assessment Report: Summary for Policymakers. United Nations Intergovernmental Panel on Climate Change. 2023. Available from: https://www.ipcc.ch/report/ar6/syr/downloads/report/IPCC_AR6_SYR_SPM.pdf

[7] Hoesung Lee KC, Dasgupta D, Gerhard, Krinner AM, *et al.* Synthesis report of the IPCC Sixth Assessment Report: Longer Report. United Nations Intergovernmental Panel on Climate Change. 2022. Available from: https://www.ipcc.ch/report/ar6/syr/downloads/report/IPCC_AR6_S

YR_LongerReport.pdf

[8]   Singh H, Eckelman M, Berwick DM, Sherman JD. Mandatory reporting of emissions to achieve net-zero health care. N Engl J Med 2022; 387(26): 2469-76.
http://dx.doi.org/10.1056/NEJMsb2210022 PMID: 36516087

[9]   Medicare Cf, Services M. FY 2023 hospital inpatient prospective payment system (IPPS) and long term care hospitals (LTCH PPS) proposed rule-CMS-1771-P2022. 2023. Available from: https://www.cms.gov/newsroom/fact-sheets/fy-2023-hospital-inpatient-prospective-payment-system-ipps-and-long-term-care-hospitals-ltch-pps (Accessed on: March 22, 2023).

[10]   Department of Health and Human Services. HHS Launches Pledge Initiative to Mobilize Health Care Sector to Reduce Emissions. 2022. Available from: https://www.hhs.gov/about/news/2022/04/22/hhs-launches-pledge-initiative-mobilize-health-care-sector-reduce-emissions.html (Accessed on: March 22, 2023).

[11]   Sakai EM, Connolly LA, Klauck JA. Inhalation anesthesiology and volatile liquid anesthetics: Focus on isoflurane, desflurane, and sevoflurane. Pharmacotherapy 2005; 25(12): 1773-88.
http://dx.doi.org/10.1592/phco.2005.25.12.1773 PMID: 16305297

[12]   Varughese S, Ahmed R. Environmental and Occupational Considerations of Anesthesia: A Narrative Review and Update. Anesth Analg 2021; 133(4): 826-35.
http://dx.doi.org/10.1213/ANE.0000000000005504 PMID: 33857027

[13]   Hodnebrog O, Aamaas B, Fuglestvedt JS, Marston G, Myhre G, Nielsen CJ, et al. Updated global warming potentials and radiative efficiencies of halocarbons and other weak atmospheric absorbers. Rev Geophys 2020; 58(3): e2019RG000691.
http://dx.doi.org/10.1029/2019RG000691 PMID: 33015672

[14]   Andersen MPS, Nielsen OJ, Sherman JD. The global warming potentials for anesthetic gas sevoflurane need significant corrections. Environ Sci Technol 2021; 55(15): 10189-91.
http://dx.doi.org/10.1021/acs.est.1c02573 PMID: 34296868

[15]   Devlin-Hegedus JA, McGain F, Harris RD, Sherman JD. Action guidance for addressing pollution from inhalational anaesthetics. Anaesthesia 2022; 77(9): 1023-9.
http://dx.doi.org/10.1111/anae.15785 PMID: 35729804

[16]   Kennedy RR. New technology in anaesthesia: Friend or foe? J Clin Monit Comput 2014; 28(2): 113-6.
http://dx.doi.org/10.1007/s10877-014-9557-7 PMID: 24458593

[17]   U.S. Food and Drug Administration. Et Control - P210018 Approval. 2022. Available from: https://www.fda.gov/medical-devices/recently-approved-devices/et-control-p210018 (Accessed on: March 22, 2023).

[18]   Feldman JM, Hendrickx J, Kennedy R. Technology and Low-Flow Anesthesia Practice. APSF Technology Education Initiative. 2022. Available from: https://www.apsf.org/article/technology-and-low-flow-anesthesia-practice/ (Accessed on: June 29, 2023).

[19]   Kandeel A, Elmorshedi M, Abdalla U, et al. Automated control of end-tidal sevoflurane in living donor hepatectomy, a prospective, randomized, controlled study. Egypt J Anaesth 2017; 33(3): 233-7.
http://dx.doi.org/10.1016/j.egja.2017.05.007

[20]   Lucangelo U, Garufi G, Marras E, Ferluga M, Turchet F, Bernabe F, et al. End-tidal versus manually-controlled low-flow anaesthesia. J Clin Monit Comput 2014; 28(2): 117-21.
http://dx.doi.org/10.1007/s10877-013-9516-8 PMID: 24114079

[21]   Mostad D, Klepstad P, Follestad T, Pleym H. Desflurane consumption with automated vapour control systems in two different anaesthesia machines. A randomized controlled study. Acta Anaesthesiol Scand 2021; 65(7): 895-901.
http://dx.doi.org/10.1111/aas.13825 PMID: 33788249

[22]   Potdar M, Kamat L, Save M. Cost efficiency of target-controlled inhalational anesthesia. J Anaesthesiol Clin Pharmacol 2014;

30(2): 222-7.
http://dx.doi.org/10.4103/0970-9185.130026 PMID: 24803762

[23]   Wetz AJ, Mueller MM, Walliser K, et al. End-tidal control vs. manually controlled minimal-flow anesthesia: a prospective comparative trial. Acta Anaesthesiol Scand 2017; 61(10): 1262-9.
http://dx.doi.org/10.1111/aas.12961 PMID: 28832896

[24]   U.S. Food and Drug Administration. Summary of safety and effectiveness data (SSED) - P210018. 2022. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210018B.pdf (Accessed on: March 22, 2023).

[25]   Community Center Cochrane Editorial and Publishing Policy Resource. 2024. Available from: https://community.cochrane.org/review-development/resources/cochrane-editorial-and-publishing-policy-resource (Accessed on: July 17, 2024).

[26]   Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. Hoboken, New Jersey, USA: John Wiley & Sons 2019; pp. 1-694.
http://dx.doi.org/10.1002/9781119536604

[27]   Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14(1): 135.
http://dx.doi.org/10.1186/1471-2288-14-135 PMID: 25524443

[28]   Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557-60.
http://dx.doi.org/10.1136/bmj.327.7414.557 PMID: 12958120

[29]   Zuegge KL, Bunsen SK, Volz LM, et al. Provider education and vaporizer labeling lead to reduced anesthetic agent purchasing with cost savings and reduced greenhouse gas emissions. Anesth Analg 2019; 128(6): e97-9.
http://dx.doi.org/10.1213/ANE.0000000000003771 PMID: 31094796

[30]   U.S. Inflation Calculator U.S. Inflation Calculator. 2022. Available from: https://www.usinflationcalculator.com/ (Accessed on: March 27, 2022).

[31]   Edmonds A, Stambaugh H, Pettey S, Daratha KB. Evidence-based project: cost savings and reduction in environmental release with low-flow anesthesia. AANA J 2021; 89(1): 27-33.
PMID: 33501906

[32]   U.S. Environmental Protection Agency. Greenhouse Gas Equivalencies Calculator. 2023. Available from: https://www.epa.gov/energy/greenhouse-gas-equivalencies-calculator#results

[33]   Reichle FM, Conzen PF, Peter K. Nephrotoxicity of halogenated inhalational anaesthetics: fictions and facts. Eur Surg Res 2002; 34(1-2): 188-95.
http://dx.doi.org/10.1159/000048908 PMID: 11867922

[34]   Sondekoppam RV, Narsingani KH, Schimmel TA, McConnell BM, Buro K, Özelsel TJP. The impact of sevoflurane anesthesia on postoperative renal function: a systematic review and meta-analysis of randomized-controlled trials. Can J Anaesth 2020; 67(11): 1595-623.
http://dx.doi.org/10.1007/s12630-020-01791-5 PMID: 32812189

[35]   Kennedy RR, Hendrickx JFA, Feldman JM. There are no dragons: Low-flow anaesthesia with sevoflurane is safe. Anaesth Intensive Care 2019; 47(3): 223-5.
http://dx.doi.org/10.1177/0310057X19843304 PMID: 31124374

[36]   Raghuraman MS. Comment on: "Automated control of end-tidal sevoflurane in living donor hepatectomy - a prospective, randomized, controlled study.". Egypt J Anaesth 2017; 33(4): 387.
http://dx.doi.org/10.1016/j.egja.2017.08.001

[37]   Loadsman J. Automated control of end-tidal sevoflurane in living donor hepatectomy a prospective, randomized, controlled study. 2023. Available from: https://pubpeer.com/publications/91B338BFADE8BC24BC071ACEC09386